Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.
Advertisement

Related Content

Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
U.K's Heptares Signs Up AstraZeneca In Latest GPCR-Focused Discovery Pact
U.K's Heptares Signs Up AstraZeneca In Latest GPCR-Focused Discovery Pact
Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
Deals Of The Week: Onyx Proteolix, Novartis/Heptares, Wyeth/Progenics ...
Kyowa Hakko’s Parkinson’s Drug Is Not Approvable – U.S. FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS072342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel